2024
Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars
Flores V, Sahin C, Taylor H. Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars. F&S Science 2024, 6: 65-72. PMID: 39393571, DOI: 10.1016/j.xfss.2024.10.004.Peer-Reviewed Original ResearchProgestin-based therapyAggressive forms of endometriosisPR lesionsProgesterone receptorGnRH antagonistMedroxyprogesterone acetatePR statusEndometriotic lesionsAggressive formResponse to MPAResponse to medical therapyPost-treatment sizeProgesterone receptor statusHuman endometriotic lesionsResponse to progestinsChronic gynecological diseaseDaily subcutaneous injectionsReproductive-age womenMouse xenograft modelResponse to medicationEndometrioma lesionsReceptor statusHormone suppressionPR expressionClinical response
2019
Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials
Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Coyne KS, Surrey ES, Taylor HS. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. American Journal Of Obstetrics And Gynecology 2019, 222: 592.e1-592.e10. PMID: 31759891, DOI: 10.1016/j.ajog.2019.11.1255.Peer-Reviewed Original ResearchConceptsEndometriosis Health Profile-30Nonmenstrual pelvic painHealth-related qualityEndometriosis-associated painPelvic painMonth 3Clinical responseClinical respondersPain symptomsMeaningful improvementsEndometriosis-related pain symptomsSevere endometriosis-associated painSevere endometriosis-related painGonadotropin-releasing hormone antagonistPhase III clinical trialsPain reduction scoresPain responder statusSelf-reported bleedingPlacebo-controlled studyEndometriosis-related painSelf-reported painWork productivityReceiver-operating characteristic analysisNumber of symptomsProductivity Questionnaire
2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. New England Journal Of Medicine 2017, 377: 28-40. PMID: 28525302, DOI: 10.1056/nejmoa1700089.Peer-Reviewed Original ResearchConceptsNonmenstrual pelvic painEndometriosis-associated painPelvic painClinical responsePercentage of womenPlacebo groupEnd pointPrimary efficacy end pointSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOral GnRH antagonistRescue analgesic agentsEfficacy end pointPrimary end pointPhase 3 trialClinical response criteriaEstrogen-dependent conditionDaily electronic diaryBone mineral densityProportion of womenCorresponding percentagesEndometrial findingsEstrogen suppressionPain scoresHot flushes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply